<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1929">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 31, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02651662</url>
  </required_header>
  <id_info>
    <org_study_id>R1979-ONC-1504</org_study_id>
    <secondary_id>2015-001697-17</secondary_id>
    <nct_id>NCT02651662</nct_id>
  </id_info>
  <brief_title>Study of REGN2810 and REGN1979 in Patients With Lymphoma</brief_title>
  <official_title>A Phase 1 Study to Assess Safety and Tolerability of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody, and REGN2810, an Anti-Programmed Death-1 Monoclonal Antibody, in Patients With B-Cell Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Regeneron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Regeneron Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, multicenter, dose escalation study of REGN2810 and REGN1979 in
      patients with lymphoma. The study treatment period will be from 6 to 12 months, depending on
      how an individual patient responds to treatment. The follow-up period will be 6 months for
      all patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 11, 2016</start_date>
  <completion_date type="Anticipated">November 6, 2020</completion_date>
  <primary_completion_date type="Anticipated">November 6, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment emergent adverse events (TEAEs)</measure>
    <time_frame>Up to 18 months</time_frame>
    <description>TEAEs include abnormal laboratory findings and dose limiting toxicities (DLTs)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) of REGN2810 when given alone, and of REGN 2810 and REGN1979 when given in combination</measure>
    <time_frame>Up to 18 months</time_frame>
    <description>PK variables of REGN2810 may include, but are not limited to, the following:
Area under the concentration-time curve (AUC) over a dosing interval, the peak concentration and last positive (quantifiable) concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antitumor activity (includes response evaluation per Cheson and Lugano criteria)</measure>
    <time_frame>Up to 18 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">172</enrollment>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>Open label (REGN2810)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental cohorts will consist of multiple dose levels of REGN2810 administered intravenously (IV) every 2 weeks (Q2W)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Open label (REGN2810 and REGN1979)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental cohorts will consist of a single dose level of REGN2810 administered intravenously (IV) and multiple dose levels of REGN1979 administered intravenously (IV)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>REGN2810</intervention_name>
    <arm_group_label>Open label (REGN2810)</arm_group_label>
    <arm_group_label>Open label (REGN2810 and REGN1979)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>REGN1979</intervention_name>
    <arm_group_label>Open label (REGN2810 and REGN1979)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria [(Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL)]:

          1. Have documented CD20+ B-cell NHL or documented HL, with active disease that is either
             not responsive to or relapsed after prior therapy, for whom no standard of care
             options exists.

          2. Must have at least 1 bi-dimensionally measurable lesion (≥1.5 cm) documented by
             diagnostic imaging (CT, PET-CT or MRI).

          3. Eastern Cooperative Oncology Group (ECOG) performance status ≤1

          4. Life expectancy of at least 6 months

          5. Adequate bone marrow function

          6. Adequate organ function

          7. Willing and able to comply with clinic visits and study-related procedures

          8. Provide signed informed consent

        Key Exclusion Criteria (NHL and HL):

          1. Primary central nervous system (CNS) lymphoma, or known or suspected CNS involvement
             by nonprimary CNS NHL

          2. History of or current relevant CNS pathology

          3. Ongoing or recent (within 2 years) evidence of significant autoimmune disease that
             required treatment with systemic immunosuppressive treatments, which may suggest risk
             for iAEs

          4. Prior allogeneic stem cell transplantation

          5. Prior treatment with an agent that blocks the programmed death-1/ programmed
             death-ligand 1 (PD-1/PD-L1 pathway), unless benefit was demonstrated

          6. Uncontrolled infection with human immunodeficiency virus (HIV), hepatitis B or
             hepatitis C infection or other uncontrolled infection

          7. History of hypersensitivity to any compound in the tetracycline antibiotics group

          8. Known hypersensitivity to both allopurinol and rasburicase

          9. Pregnant or breastfeeding women

         10. Continued sexual activity in men or women of childbearing potential who are unwilling
             to practice adequate contraception during the study

         11. Prior treatment with idelalisib
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trial Management</last_name>
    <role>Study Director</role>
    <affiliation>Regeneron Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Trials Administrator</last_name>
    <email>clinicaltrials@regeneron.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Regeneron Research Facility</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Research Facility</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Research Facility</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Research Facility</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Research Facility</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Research Facility</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Research Facility</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Research Facility</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Research Facility</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Research Facility</name>
      <address>
        <city>Cologne</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Research Facility</name>
      <address>
        <city>Frankfurt</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Research Facility</name>
      <address>
        <city>Jena</city>
        <zip>07747</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Research Facility</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Research Facility</name>
      <address>
        <city>Würzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Research Facility</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Research Facility</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Research Facility</name>
      <address>
        <city>Majadahonda</city>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Research Facility</name>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 5, 2016</study_first_submitted>
  <study_first_submitted_qc>January 7, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 11, 2016</study_first_posted>
  <last_update_submitted>September 10, 2018</last_update_submitted>
  <last_update_submitted_qc>September 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Bispecific</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

